Mark Samuels, our Chief Business & Strategy Officer, was recently profiled in PharmaTimes sharing his views on how the Medicines Discovery Catapult is helping bring about the future of drug discovery.
“As well as the practicalities – such as managing teams of R&D scouts and handling IP – open innovation requires significant cultural change. Working in a highly collaborative manner is a big change for many companies and cultural change is traditionally very difficult. However, I’m hopeful that the need to develop new medicines will catalyse open innovation, resulting in increased R&D productivity. The Medicines Discovery Catapult is able to smooth the way and help SMEs in particular with collaborative R&D.”
Read the full article in PharmaTimes.
